The company has plenty of cash now. Talk of a CR before any trial results is just unrealistic.
The directors literally introduced a new technology to imugene and the company received a 3m USD cash injection because of it. https://bioshares.com.au/blog/imugene-to-acquire-fourth-technology-platform?ListPageUrl=https://bioshares.com.au:443/premium-biotech-coverage/current-news
As for the share price falling from ipo we'll ye, small company in a sector that's has been demolished. Ultimately these small biotechs either succeed and return many times your investment or they go to 0. To expect anything else is delusional. However I do think from here you can reasonably safely buy in, sell your principle out later on without seeing it through to the end and keep the ticket. At this stage though the results look promising and my current intention is to hold until product release or buyout.
CHM Price at posting:
2.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)